These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28070733)

  • 41. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S146-S155. PubMed ID: 29693361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
    Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
    Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.
    Weiss T; Carr RD; Pal S; Yang L; Sawhney B; Boggs R; Rajpathak S; Iglay K
    Patient Prefer Adherence; 2020; 14():2337-2345. PubMed ID: 33273810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes.
    Romera I; Cebrián-Cuenca A; Álvarez-Guisasola F; Gomez-Peralta F; Reviriego J
    Diabetes Ther; 2019 Feb; 10(1):5-19. PubMed ID: 30506340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GLP-1 receptor agonists: a review of head-to-head clinical studies.
    Trujillo JM; Nuffer W; Ellis SL
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):19-28. PubMed ID: 25678953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.
    Wittbrodt ET; Eudicone JM; Farahbakhshian S; McAdam-Marx C
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S156-S164. PubMed ID: 29693362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.
    Boye KS; Botros FT; Haupt A; Woodward B; Lage MJ
    Diabetes Ther; 2018 Apr; 9(2):637-650. PubMed ID: 29460259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.
    Miller E; Chuang JS; Roberts GJ; Nabutovsky Y; Virdi N; Wright EE
    Diabetes Ther; 2024 Jul; ():. PubMed ID: 39008235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.
    Gleason PP; Urick BY; Marshall LZ; Friedlander N; Qiu Y; Leslie RS
    J Manag Care Spec Pharm; 2024 May; ():1-8. PubMed ID: 38717042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis.
    Wilke T; Mueller S; Groth A; Berg B; Fuchs A; Sikirica M; Logie J; Martin A; Maywald U
    Diabetes Ther; 2016 Mar; 7(1):105-24. PubMed ID: 26695499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes.
    Tonoike M; Chujo D; Noda M
    Endocrinol Diabetes Metab; 2019 Jan; 2(1):e00043. PubMed ID: 30815572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy.
    Wu R; Wu Z; Xing L; Liu X; Wu L; Zhou Z; Li L; Huang Y
    Asian J Pharm Sci; 2022 Aug; 17(5):653-665. PubMed ID: 36382301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.
    Kiiskinen U; Matthaei S; Reaney M; Mathieu C; Ostenson CG; Krarup T; Theodorakis M; Kiljański J; Salaun-Martin C; Sapin H; Guerci B
    Clinicoecon Outcomes Res; 2013; 5():355-67. PubMed ID: 23874113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus.
    Brice R; Shelley S; Chaturvedi P; Glah D; Ashley D; Hadi M
    Drugs Context; 2015; 4():212269. PubMed ID: 25657811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.
    Kalra S; Das AK; Sahay RK; Baruah MP; Tiwaskar M; Das S; Chatterjee S; Saboo B; Bantwal G; Bhattacharya S; Priya G; Chawla M; Brar K; Raza SA; Aamir AH; Shrestha D; Somasundaram N; Katulanda P; Afsana F; Selim S; Naseri MW; Latheef A; Sumanatilleke M
    Diabetes Ther; 2019 Oct; 10(5):1645-1717. PubMed ID: 31359367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lira and Naimi Respond.
    Lira MC; Naimi TS
    Am J Public Health; 2022 Apr; 112(4):e2-e3. PubMed ID: 35319945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.